Finding new treatments for platinum-resistant ovarian cancer using T-cell therapy
Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer
This study is looking for new ways to help patients with tough-to-treat ovarian cancer by analyzing their tumor samples to find specific targets that can be attacked by the immune system, which could lead to better treatments for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11115806 on NIH RePORTER |
What this research studies
This research focuses on developing T-cell receptor (TCR) therapies specifically for patients with platinum-resistant high-grade serous ovarian carcinoma (HGSOC), a challenging cancer with limited treatment options. The approach involves analyzing the unique variations in RNA and proteins produced by cancer cells to identify new targets for immunotherapy. By utilizing advanced long-read RNA sequencing, the researchers aim to uncover cancer-specific antigens that can be targeted by T-cells, potentially leading to more effective treatments for this aggressive cancer. Patients will be involved in the study as their tumor samples will be analyzed to discover these new therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with platinum-resistant high-grade serous ovarian carcinoma who have experienced disease recurrence after initial platinum-based treatment.
Not a fit: Patients with other types of ovarian cancer or those who have not been treated with platinum-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for patients with platinum-resistant ovarian cancer, improving their treatment outcomes.
How similar studies have performed: Other research has shown promise in utilizing T-cell therapies and RNA sequencing for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Memarzadeh, Sanaz — University of California Los Angeles
- Study coordinator: Memarzadeh, Sanaz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.